Abstract: Described herein are topical cream formulations that include a C7-20 alkane, a metal chelating agent, and a buffer.

Abstract: The invention relates to the use of nitric oxide releasing cyclic guanosine 3?,5? monophosphate (cGMP) phosphodiesterase type 5 inhibitors (NO-PDES inhibitors) in a method for the treatment of dry age-related macular degeneration and geographic atrophy. This invention also relates to the use of such compounds to provide neuroprotection to the eye in a patient suffering from glaucoma or retinal neuropathies.

Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat intraocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject’ eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.

Abstract: The present disclosure relates to the field of pharmaceutical compositions, ocular implants, and systems and methods for treating an ocular condition. In certain aspects, the disclosure provides ocular implant systems for treating post-operative inflammation. In certain aspects, the ocular implants taught herein are rapid release extended treatment implants.

Abstract: A disclosed computing device is configured to: in response to an actuation of a first set of keys on a keyboard, navigating to and selecting an embedded code editor on a web page, wherein the code editor transitions from an unfocused state on the web page to a focused and read-only state on the web page; in response to an actuation of a second set of keys on the keyboard, activating the code editor, wherein the code editor transitions from the focused and read-only state on the web page to a focused and editable state on the web page; and in response to an actuation of a third set of keys on the keyboard, deactivating the code editor, wherein the code editor transitions from the focused and editable state on the web page to the focused and read-only state on the web page.

Abstract: The invention relates to an adjustment device (1), comprising at least two linear stages (2, 3), which are arranged next to each other and which are fixedly connected to each other (6) by means of one of the adjustment sections (5) of each of the linear stages such that an adjustment movement of one linear stage can be transferred to the adjacent linear stage, wherein one linear stage is designed to bring about an increase in the distance between the adjustment sections arranged on said linear stage as a result of actuation of the adjustment element and an adjacent linear stage is designed to bring about a decrease in the distance between the adjustment sections arranged on said linear stage as a result of actuation of the adjustment element so that a displacement of the adjustment device can be realized, which displacement corresponds to the sum of the amounts of the changes in the distance between the adjustment sections of the linear stages.

Abstract: An adjusting device is provided for positioning an object. The adjusting device includes a base and a supply line. The base is configured to move an object that is connectable to the base in the connected state along a path of motion in a position-controlled manner. The supply line supplies the energy and/or signal transmission to and/or from the base. The supply line is coupled to the base in a reversibly detachable manner.

Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Abstract: The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The invention relates to an adjustment device (1), comprising at least two linear stages (2, 3), which are arranged next to each other and which are fixedly connected to each other (6) by means of one of the adjustment sections (5) of each of the linear stages such that an adjustment movement of one linear stage can be transferred to the adjacent linear stage, wherein one linear stage is designed to bring about an increase in the distance between the adjustment sections arranged on said linear stage as a result of actuation of the adjustment element and an adjacent linear stage is designed to bring about a decrease in the distance between the adjustment sections arranged on said linear stage as a result of actuation of the adjustment element so that a displacement of the adjustment device can be realized, which displacement corresponds to the sum of the amounts of the changes in the distance between the adjustment sections of the linear stages.

Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat ocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject' eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.

Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.

Abstract: Embodiments described herein relate generally to medical implant delivery apparatuses and methods. In some embodiments, an apparatus comprises a first cap, a needle hub at least partially disposed within the first cap, a pusher wire and a pusher wire connector disposed within the needle hub, a needle and a second cap. The first cap includes a proximal end, a distal end, and a longitudinal axis. The needle includes a first, beveled end configured to receive an implant, and a second end disposed within a hub pocket of the needle hub. The second cap is connected to the needle hub and disposed at a proximal end of the first cap. The pusher wire, the pusher wire connector, and the needle are substantially aligned with one another along the longitudinal axis of the first cap. In some embodiments, the pusher wire is sized to be received in the bore of the needle.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Abstract: An intracameral injector needle having a substantially cylindrical body defining a longitudinal flow path therein, and having a proximal end, a distal end, an outer peripheral face and a bevel region. A first bevel of the bevel region has a first bevel angle with respect to the outer peripheral face. A second bevel of the bevel region extends from the first bevel to the proximal end. The second bevel includes a tip of the intracameral injector needle, and has a second bevel angle with respect to the outer peripheral face, where the second bevel angle is different from the first bevel angle, the first bevel and the second bevel defining a transition therebetween. The transition is at least one of: (1) longitudinally positioned between the tip of the intracameral injector needle and a location of a maximum width of the bevel region; and (2) vertically disposed at a position below 50% of a maximum height of the bevel region.